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Summary
Background Tracking of aid resources to reproductive, maternal, newborn, and child health (RMNCH) provides timely 
and crucial information to hold donors accountable. For the ﬁ rst time, we examine ﬂ ows in oﬃ  cial development 
assistance (ODA) and grants from the Bill & Melinda Gates Foundation (collectively termed ODA+) in relation to the 
continuum of care for RMNCH and assess progress since 2003.
Methods We coded and analysed ﬁ nancial disbursements for maternal, newborn, and child health (MNCH) and for 
reproductive health (R*) to all recipient countries worldwide from all donors reporting to the creditor reporting 
system database for the years 2011–12. We also included grants from the Bill & Melinda Gates Foundation. We 
analysed trends for MNCH for the period 2003–12 and for R* for the period 2009–12.
Findings ODA+ to RMNCH from all donors to all countries worldwide amounted to US$12·2 billion in 2011 (an 
11·8% increase relative to 2010) and $12·8 billion in 2012 (a 5·0% increase relative to 2011). ODA+ to MNCH 
represents more than 60% of all aid to RMNCH. ODA+ to projects that have newborns as part of the target population 
has increased 34-fold since 2003. ODA to RMNCH from the 31 donors, which have reported consistently since 2003, 
to the 75 Countdown priority countries, saw a 3·2% increase in 2011 relative to 2010 ($8·3 billion in 2011), and an 
11·8% increase in 2012 relative to 2011 ($9·3 billion in 2012). ODA to RMNCH projects has increased with time, 
whereas general budget support has continuously declined. Bilateral agencies are still the predominant source of 
ODA to RMNCH. Increased funding to family planning, nutrition, and immunisation projects were noted in 2011 
and 2012. ODA+ has been targeted to RMNCH during the period 2005–12, although there is no evidence of 
improvements in targeting over time.
Interpretation Despite a reduction in ODA+ in 2011, ODA+ to RMNCH increased in both 2011 and 2012. The increase 
in funding is encouraging, but continued increases are needed to accelerate progress towards achieving MDGs 4 and 
5 and beyond.
Funding Bill & Melinda Gates Foundation.
Copyright Arregoces et al. Open access article published under the terms of CC BY.
Introduction
With only 6 months remaining to reach the 2015 deadline 
of the Millennium Development Goals (MDGs), progress 
on the targets for child survival (MDG 4) and maternal 
and reproductive health (MDG 5) has been uneven. 
Achievements include almost halving child and maternal 
mortality since 2000, but further eﬀ orts are required to 
drive down mortality and increase access to reproductive 
health services.1,2 Oﬃ  cial development assistance (ODA), 
as well as private foundation grant making for global 
health, surged after the MDG summit in 2000, but the 
extended period of economic austerity since 2007–08 has 
slowed the growth of this aid.3
However, high level commitments have been made 
since 2010 to accelerate progress on MDGs 4 and 5. 
These include pledges of US$40 billion from 2010–15 
towards the Global Strategy for Women’s and Children’s 
Health, incorporating $5 billion promised by the G8 and 
other donors, including the Bill & Melinda Gates 
Foundation under the Muskoka Initiative.4 Although 
welcomed, these pledges might fall short of the estimated 
annual requirements to meet the health-related MDGs of 
between $10 billion and $33·9 billion.5–8
There has been growing attention to resource tracking 
and assessment of whether commitments are honoured, 
with initiatives undertaken by the Institute for Health 
Metrics and Evaluation (IHME),9 the Partnership for 
Maternal, Newborn and Child Health (PMNCH),6 and 
the Resource Flows project of the United Nations 
Population Fund (UNFPA) and the Netherlands 
Interdisciplinary Demographic Institute (NIDI). This 
paper contributes to these accountability eﬀ orts and 
seeks to understand whether donor resources are better 
targeted to countries with the highest need as we 
approach 2015. We build on past analyses undertaken for 
the Countdown to 2015 initiative to track donor funding 
to reproductive, maternal, newborn, and child health 
(RMNCH) con sidering the full continuum of care, with a 
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particular focus on the 75 Countdown countries where 
more than 95% of all maternal and child deaths occur.10,11 
We analyse trends in donor funding to MNCH for the 
period 2003–12 and to reproductive health for the period 
2009–12.
Methods
Data sources
ODA disbursement data for 2011 and 2012 were 
downloaded from the creditor reporting system of the 
Organisation for Economic Co-operation and 
Development (OECD) on March 12, 2014. Disbursement 
data from the Bill & Melinda Gates Foundation were 
downloaded from the same source on June 24, 2014. We 
tracked disbursements to all recipient countries 
worldwide (147 countries in 2011 and 148 in 2012), from 
all donors reporting to the creditor reporting system 
(47 donors in 2011 and 49 in 2012). We also reviewed 
private grants from the Bill & Melinda Gates Foundation, 
which began reporting to the creditor reporting system 
in 2009. Although grants from the Bill & Melinda Gates 
Foundation are not regarded as ODA, these projects are 
included in our analyses and estimates from previous 
years updated accordingly. We refer to ODA+ when 
reporting aggregated results that include these grants. 
We also analysed data for disbursements from the 
31 donors (23 bilateral, six multilaterals, and two global 
health initiatives) that have reported to the creditor 
reporting system consistently since we began this 
resource-tracking exercise, to the Countdown priority 
countries, of which there are now 75, including South 
Sudan in 2011, which had previously been included 
within data reported for Sudan. To avoid double counting, 
the OECD deﬁ nitions were used to classify aid as 
bilateral, where the recipient country or purpose of aid is 
speciﬁ ed by the donor government, and as multilateral 
for disbursements from multilateral institutions with 
governmental membership where the recipient country 
or purpose of aid is speciﬁ ed by the multilateral 
institution. The allocation of unspeciﬁ ed regional 
disbursements to individual recipient countries was 
based on their year-speciﬁ c share of direct regional 
disbursements.12
Data coding
We scanned and coded 507 954 disbursement records for 
the period 2011 and 2012 across all sectors, including 
5858 records from the Bill & Melinda Gates Foundation, 
according to a previously developed framework.12–15 The 
2003–10 datasets were not updated, thus any changes to 
the datasets by the OECD since the initial download were 
not analysed. Reproductive health expenditures (termed 
R*) included expenditures on family planning, sexual 
health, and sexually transmitted infections, including 
HIV.16 Maternal and newborn health expenditures 
included activities to restore, improve, and maintain the 
health of women and their newborns during pregnancy, 
childbirth, and the ﬁ rst month of life.15 Expenditures for 
child health included activities to restore, improve, and 
maintain the health of children up to 5 years of age.15 
Where age was unclear, we assumed the term child 
referred to children younger than 5 years. To identify 
expenditures that mentioned or exclusively beneﬁ ted 
newborns, an automated key term search was applied to 
the full creditor reporting system dataset.17 Such 
expenditures were classiﬁ ed as exclusively beneﬁ ting 
newborns, or as inclusive if they also aimed to improve 
the health of other population groups. Funding for 
research activities was excluded.
To maximise coding consistency across years, we 
compared records from 2011 and 2010, and 2012 and 2011 
with an exact string non-case-sensitive matching system. 
Where records shared the same donor and recipient 
country name, project title, and short description, the 2010 
(2011) code was assigned to the 2011 (2012) record. Slightly 
more than 35% of each year’s records were coded in this 
way. Remaining records were manually coded by four 
coders by reading the project title, and short and long 
descriptions prior to assigning a code. Intercoder 
consistency was evaluated with Krippendorﬀ ’s α on a 
sample of 1270 records. A value of more than 0·9 was 
noted among three of the coders, with the remaining coder 
scoring 0·7. All records coded by this coder were recoded 
by a second coder, and diﬀ erences solved by discussion.
As in previous years, we included funding exclusively 
earmarked for RMNCH and allocated a share of other 
activities thought to beneﬁ t RMNCH, including funds 
for general health systems or health care, general 
budget support, basket or health sector funding (eg, 
(such as the sector wide approach [SWAp]), and some 
condition-speciﬁ c funding (for example, malaria and 
HIV). Country-speciﬁ c allocation factors were used for 
condition-speciﬁ c funding based on the latest estimates 
of the crude birth rate; the total under-5 population;18 
the number of children and people of reproductive age 
living with HIV; and the prevalence of people living 
with any of four sexually transmitted diseases 
(Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis, 
and Trichomonas vaginalis).19,20 For general budget 
support, allocation factors were obtained from the 
National Health Accounts database. The allocation of 
health systems funds and basket or sector funding was 
ﬁ xed across countries and based on the literature.12
Statistical analysis
We analysed trends in donor funding to MNCH for the 
period 2003–12 and to R* for the period 2009–12. We 
examined variation in funding levels with time for every 
donor and by donor type (bilateral, multilateral, global 
health initiative, and private foundation). We also 
analysed trends in funding by modality (pooled funding 
vs project funding), and by project type. Finally, we 
considered variation in funding levels to recipient 
countries and regions over time. All data from the 
For the OECD creditor reporting 
system see http://stats.oecd.org/
index.aspx?DataSetCode=CRS1
For the WHO Global Health 
Expenditure Database see http://
apps.who.int/nha/database
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period 2003–12 were converted to constant 2012 US$ 
with the donor-speciﬁ c development assistance 
committee deﬂ ators.21
We assessed the extent to which donors targeted their 
development assistance based on country need and 
whether targeting improved with time. A series of 
univariate ordinary least squares regressions were 
estimated to evaluate whether ODA+ was targeted to 
countries with higher under-5 mortality rates,22 higher 
maternal mortality,23 higher HIV prevalence,19 and lower 
female life expectancy at birth24 for 3 years, 2005, 2010, 
and 2012. Disbursements from all donors to all countries 
receiving ODA+ were included. The ﬁ rst model used the 
natural logarithm of ODA+ to child health per child as the 
dependant variable and the under-5 mortality rate (deaths 
per 1000 children younger than 5 years) as the 
independent variable; the second model used the natural 
logarithm of ODA+ to maternal and newborn health per 
livebirth as the dependant variable and the maternal 
mortality ratio (maternal deaths per 100 000 livebirths) as 
the independent variable; and the third and fourth models 
used the natural logarithm of ODA+ to reproductive 
health per woman of reproductive age as the dependant 
variable and HIV prevalence (model 3) and female life 
expectancy at birth (model 4) as the independent variables. 
The Huber-White sandwich estimator was used to deal 
with heteroskedasticity after transforming the dependant 
variable. Targeting according to need was assessed in 
relation to the sign and signiﬁ cance (p<0·05) of the 
coeﬃ  cient on the independent variable, a positive sign on 
the coeﬃ  cient of the ﬁ rst three models and a negative 
sign in the fourth model. Targeting was considered to 
have improved with time if there was an increase in the 
R² value between years, indicating a better ﬁ t of the data. 
We tested the signiﬁ cance of the diﬀ erence in the R² 
value between years using Fischer’s Z transformation of 
correlation coeﬃ  cients followed by a t test for the null 
hypothesis that the diﬀ erence is equal to zero. We also 
examined whether targeting diﬀ ered across types of 
donor (multilateral, bilateral, global health initiatives, and 
 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Worldwide*
All ODA+ (excluding debt 
forgiveness)
78 306 86 261 101 887 114 716 110 460 124 263 140 174 146 989 146 899 148 221
ODA+ for health (% of all 
ODA+)
7604
(9·7%)
8614
(10·0%)
11 046
(10·8%)
12 426
(10·8%)
14 186
(12·8%)
15 599
(12·6%)
19 118
(13·6%)
20 217
(13·8%)
20 661
(14·1%)
21 512
(14·5%)
ODA+ for RMNCH (% of all 
ODA+ to health)
·· ·· ·· ·· ·· ·· 10 810
(56·5%)
10 947
(54·1%)
12 234
(59·2%)
12 843
(59·7%)
ODA+ for R* (% of all ODA+ 
to health)
·· ·· ·· ·· ·· ·· 3587
(18·8%)
3805
(18·8%)
4674
(22·6%)
4499
(20·9%)
ODA+ for MNCH (% of all 
ODA+ to health)
2673
(35·2%)
2689
(31·2%)
3673
(33·3%)
4455
(35·9%)
4770
(33·6%)
5529
(35·4%)
7222
(37·8%)
7142
(35·3%)
7561
(36·6%)
8345
(38·8%)
ODA+ for MNH (% of ODA+ 
to MNCH)
930
(34·8%)
737
(27·4%)
1333
(36·3%)
1507
(33·8%)
1589
(33·3%)
1693
(30·6%)
2303
(31·9%)
2198
(30·8%)
2024
(26·8%)
2392
(28·7%)
ODA+ for CH (% of ODA+ to 
MNCH)
1743
(65·2%)
1952
(72·6%)
2340
(63·7%)
2948
(66·2%)
3181
(66·7%)
3836
(69·4%)
4920
(68·1%)
4945
(69·2%)
5536
(73·2%)
5953
(71·3%)
75 Countdown priority countries†
ODA for RMNCH (% of all 
ODA+ to health)
·· ·· ·· ·· ·· ·· 7715
(40·4%)
8049
(39·8%)
8305
(40·2%)
9289
(43·2%)
ODA for R* (% of all ODA+ to 
health)
·· ·· ·· ·· ·· ·· 2615
(13·7%)
2828
(14·0%)
3021
(14·6%)
3119
(14·5%)
ODA for MNCH (% of all 
ODA+ to health)
2047
(26·9%)
2224
(25·8%)
2936
(26·6%)
3627
(29·2%)
3641
(25·7%)
4367
(28·0%)
5101
(26·7%)
5221
(25·8%)
5284
(25·6%)
6170
(28·7%)
ODA to CH (% of ODA to 
MNCH)
1399
(68·3%)
1634
(73·5%)
1929
(65·7%)
2453
(67·6%)
2467
(67·8%)
3027
(69·3%)
3552
(69·6%)
3640
(69·7%)
3819
(72·3%)
4374
(70·9%)
ODA to MNH (% of ODA to 
MNCH)
648
(31·7%)
590
(26·5%)
1006
(34·3%)
1174
(32·4%)
1174
(32·2%)
1340
(30·7%)
1548
(30·4%)
1582
(30·3%)
1465
(27·7%)
1796
(29·1%)
ODA for projects exclusively 
targeted to newborns (% of 
ODA to MNCH)
0·85
(0·04%)
2·82
(0·1%)
0·19
(0·01%)
0·78
(0·02%)
0·30
(0·01%)
5·66
(0·1%)
3·80
(0·1%)
3·94
(0·1%)
4·55
(0·1%)
6·01
(0·1%)
ODA for projects that 
mention newborns (% of 
ODA to MNCH)
33
(1·6%)
41
(1·8%)
72
(2·4%)
59
(1·6%)
65
(1·8%)
258
(5·9%)
380
(7·4%)
510
(9·8%)
552
(10·5%)
1136
(18·4%)
Values are in constant 2012 US$ (millions). ODA+=oﬃ  cial development assistance plus the grants from the Bill & Melinda Gates Foundation. CH=child health. MNH=maternal 
and newborn health. MNCH=maternal, newborn, and child health. R*=reproductive health. ODA=oﬃ  cial development assistance. *ODA+ from all donors reporting to the 
creditor reporting system of the Organisation for Economic Co-operation and Development in that year to all countries. †ODA from 31 donors that have consistently 
reported since 2003 to the 75 Countdown priority countries.
Table 1: ODA+ and ODA to reproductive, maternal, newborn, and child health, 2003–12 
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2003 
(MNCH)
2004 
(MNCH)
2005 
(MNCH)
2006 
(MNCH)
2007 
(MNCH)
2008 
(MNCH)
2009 2010 2011 2012
MNCH R* MNCH R* MNCH R* MNCH R*
Bilateral aid 
agencies
1597·9 1454·4 2069·5 2111·0 2925·9 3338·7 3924·1 2779·6 3787·4 2795·3 3985·9 3615·7 4197·1 3325·7
Australia* 75·3 65·3 7·3 129·8 78·8 81·5 137·8 25·0 205·5 36·9 177·2 72·0 291·4 53·8
Austria* 4·0 4·5 5·1 6·9 7·3 6·1 5·8 1·0 5·6 0·6 10·6 0·2 4·0 0·1
Belgium* 14·6 0·8 31·7 38·1 54·3 43·1 46·3 12·4 55·5 10·9 54·7 9·6 45·2 3·1
Canada* 86·0 103·7 142·4 134·7 281·2 238·0 320·7 34·2 284·6 22·1 491·1 15·8 507·4 14·8
Czech Republic ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 1·1 0·0 1·8 0·3
Denmark* 0·0 30·6 38·4 32·6 32·8 35·2 68·0 19·6 67·4 30·1 58·2 35·7 49·6 16·9
Finland* 9·3 0·0 0·0 17·7 20·0 22·8 22·0 2·1 21·1 5·7 20·1 6·2 17·5 7·1
France* 54·5 69·6 47·6 10·5 38·6 54·4 64·4 10·7 53·8 8·6 87·1 8·3 91·8 7·9
Germany* 76·9 41·3 68·4 90·1 123·8 160·9 168·7 54·5 201·1 78·0 133·5 69·2 194·1 72·5
Greece* 18·0 2·8 14·5 7·8 13·5 2·8 6·7 3·5 11·4 4·2 0·8 0·0 0·0 0·0
Iceland ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 1·1 0·2 1·2 0·0
Ireland* 19·8 29·8 25·6 29·4 51·9 39·0 38·7 18·0 37·6 14·2 42·8 15·5 36·2 12·7
Italy* 26·2 26·1 3·2 32·7 41·2 44·5 42·8 6·0 41·3 2·8 33·2 5·3 24·0 2·0
Japan* 146·6 110·4 107·6 208·0 252·1 176·0 245·9 17·5 236·8 15·4 345·3 18·1 235·8 6·3
Korea* ·· ·· ·· 13·8 15·5 25·8 42·9 2·0 47·1 2·5 33·5 0·2 44·4 1·3
Kuwait ·· ·· ·· ·· ·· ·· ·· ·· 8·5 0·0 6·7 0·0 1·7 0·0
Luxembourg*  0·0 15·7 15·6 18·3 31·5 26·1 21·2 4·8 27·5 1·2 12·3 2·3 14·2 1·5
Netherlands* 88·6 67·3 87·6 86·0 123·5 112·4 162·5 57·2 112·6 57·5 105·8 72·1 97·6 44·0
New Zealand* 4·9 9·1 8·9 10·2 5·0 11·5 13·6 2·1 14·5 2·2 11·8 3·3 11·1 4·1
Norway* 57·8 49·4 53·0 69·1 88·7 105·2 174·0 31·3 115·4 24·0 110·6 31·4 105·7 22·3
Portugal* 2·4 2·8 4·0 2·8 1·0 1·6 2·4 0·0 5·0 0·4 7·0 0·2 7·2 0·0
Spain* 45·2 43·3 57·0 64·9 163·5 171·0 159·6 17·3 139·4 14·3 54·0 12·0 33·1 3·4
Sweden* 43·7 53·8 80·3 85·7 105·5 92·8 108·1 44·2 87·5 35·8 61·6 48·9 171·5 42·8
Switzerland* 23·6 26·1 17·1 33·3 26·2 31·5 36·4 2·5 35·9 2·1 40·6 5·4 44·1 5·1
United Arab 
Emirates
30·5 0·1 19·4 0·3 12·0 0·0 51·5 0·0
UK* 240·1 184·3 332·1 312·7 331·1 425·4 585·5 135·3 500·5 140·7 601·6 259·8 762·2 223·2
USA* 560·3 517·8 922·3 676·0 1038·8 1431·1 1419·7 2278·4 1452·3 2284·9 1471·6 2924·2 1353·1 2780·5
Multilateral aid 
agencies
866·3 875·5 1027·5 1789·1 1122·2 1081·2 1624·0 294·3 1472·2 234·7 1586·0 287·1 1648·8 237·1
AfDB ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 0·3 0·0 0·1 0·0
AfDF ·· ·· 0·0 ·· 0·0 52·6 58·3 2·6 43·4 3·9 48·6 2·7 40·0 1·1
Arab Fund 
(AFESD)
·· ·· ·· ·· ·· ·· ·· ·· 0·9 0·0 1·1 0·0 1·5 0·0
AsDB Special 
Funds
·· ·· ·· ·· ·· ·· ·· ·· 84·2 3·7 50·7 2·2 35·4 0·3
BADEA ·· ·· ·· ·· ·· ·· ·· ·· ·· ·· 2·7 0·0 0·9 0·0
EU institutions* 67·6 74·5 172·8 335·9 257·7 351·6 399·4 25·0 393·8 21·7 550·1 14·5 748·2 31·8
GEF ·· ·· ·· ·· ·· 0·3 ·· ·· ·· ·· ·· ·· 0·1 0·0
IDA* 460·8 631·8 543·7 1171·6 411·5 334·0 550·1 103·9 350·3 76·7 375·5 85·7 359·9 60·4
IDB Sp Fund ·· ·· ·· ·· ·· ·· 11·2 0·0 10·6 0·0 29·7 0·0 19·2 0·0
IMF 
(concessional 
trust funds)
·· ·· ·· ·· ·· ·· ·· ·· 43·7 0·0 42·9 0·0 39·1 0·0
IMF (SAF/ESAF/
PRGF)
·· ·· ·· ·· ·· ·· 89·2 0·0 ·· ·· ·· ·· ·· ··
OFID ·· ·· ·· ·· ·· ·· 11·2 0·0 8·9 1·0 4·5 4·4 9·8 2·4
UNAIDS* 4·2 4·0 3·4 3·1 3·9 3·9 2·0 99·6 4·3 72·0 10·7 106·2 8·1 55·0
UNDP* ·· 0·5 0·3 0·4 0·8 1·2 1·2 8·0 0·6 4·9 1·4 6·1 1·5 4·6
UNECE ·· ·· ·· ·· ·· 0·1 ·· ·· 0·2 0·0 0·0 0·0 0·2 0·0
(Table 2 continues on next page)
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private donor) by running the same set of regressions for 
each type of donor. All models were run in Stata 
version 13.
Role of the funding source
The funder had no role in the study design, data extraction, 
data analysis, data interpretation, or writing of the report. 
All authors reviewed drafts of the manuscript, and the 
corresponding author had ﬁ nal responsibility to submit 
for publication. All authors had full access to the dataset. 
Results
Reported ODA+ from all donors to all sectors and 
recipients reduced slightly in 2011 relative to 2010 for the 
ﬁ rst time since 2007, and increased only marginally 
(0·9%) in 2012 (table 1; appendix pp 1, 2). However, 
development assistance to health continued to increase, 
albeit at a slower rate than previous years, representing 
an increasing share of overall ODA+ (13·8% in 2010, 
14·1% in 2011, and 14·5% in 2012; table 1).
ODA+ to RMNCH from all donors to all recipient 
countries amounted to $12·2 billion in 2011, an 11·8% 
increase relative to 2010 ($10·9 billion; table 1; appendix 
pp 1, 2). ODA+ to RMNCH increased to $12·8 billion in 
2012, a 5·0% increase relative to 2011. ODA+ to MNCH 
represented greater than 60% of RMNCH, at $7·6 billion 
in 2011 and $8·3 billion in 2012 (table 1). ODA+ to 
MNCH increased by 5·9% in 2011 relative to 2010 and by 
10·4% in 2012 relative to 2011 (appendix p 2). 2011 saw a 
7·9% drop in funds to maternal and newborn health 
relative to 2010 (from $2·2 billion to $2·0 billion), while 
funds to child health increased by 12·0% (from 
$4·9 billion to $5·5 billion; table 1; appendix p 2). 
However, funds to maternal and newborn health 
increased again in 2012 relative to 2011 by 18·2% up to 
$2·4 billion (table 1; appendix p 2). Funding to R* rose to 
$4·7 billion in 2011 (up from $3·8 billion in 2010, an 
increase of 22·8%), but decreased in 2012 to $4·5 billion 
(down by 3·7% relative to 2011; table 1; appendix pp 1, 2).
The 75 Countdown priority countries received 
$8·3 billion in ODA to RMNCH in 2011 from the 
31 donors reporting consistently since 2003 (a 3·2% 
increase relative to 2010), and $9·3 billion in 2012 (an 
11·8% increase relative to 2011; table 1; appendix p 2). 
They received $5·3 billion in ODA to MNCH in 2011 and 
$6·2 billion in 2012 (table 1). Between 2010 and 2011, 
ODA to child health to the 75 priority countries increased 
by 4·9%, and ODA to maternal and newborn health 
reduced by 7·4%, resulting in an overall increase in ODA 
to MNCH of 1·2% (appendix p 2). However, we noted a 
sharp increase in ODA to child health and to maternal 
and newborn health in 2012 (an increase by 14·5% and 
22·6%, respectively, relative to 2011 levels; appendix p 2). 
ODA to R* in the priority countries increased steadily up 
to $3·0 billion in 2011 (6·8% increase relative to 2010), 
and to $3·1 billion in 2012 (3·2 % increase relative to 
2003 
(MNCH)
2004 
(MNCH)
2005 
(MNCH)
2006 
(MNCH)
2007 
(MNCH)
2008 
(MNCH)
2009 2010 2011 2012
MNCH R* MNCH R* MNCH R* MNCH R*
(Continued from previous page)
UNFPA* 235·4 73·2 193·0 180·3 146·2 136·9 148·3 41·4 143·1 36·6 130·5 49·4 114·6 63·1
UNICEF* 98·2 91·4 114·3 97·9 302·0 200·6 182·4 7·3 186·8 9·9 147·1 11·4 121·5 8·3
UNPBF ·· ·· ·· ·· ·· ·· ·· ·· 0·1 0·0 0·0 0·3 0·0 0·2
UNRWA ·· ·· ·· ·· ·· ·· ·· ·· 48·9 0·0 47·5 0·0 24·5 0·0
WFP ·· ·· ·· ·· ·· ·· 22·2 6·5 29·3 4·3 0·2 3·6 0·1 3·7
WHO ·· ·· ·· ·· ·· ·· 148·6 0·0 123·2 0·0 142·5 0·5 124·1 6·2
Global health 
initiatives
208·8 358·8 576·4 554·7 721·9 1109·1 1296·4 483·4 1506·8 732·8 1248·7 642·1 1790·8 789·5
GAVI* 152·0 222·9 244·4 213·4 353·5 655·2 475·4 0·0 697·4 0·0 712·0 0·2 958·0 0·0
Global Fund* 56·9 135·9 332·0 341·4 368·4 453·9 821·0 483·4 809·4 732·8 536·6 641·9 832·8 789·5
Private donors ·· ·· ·· ·· ·· ·· 377·8 30·1 376·1 42·0 740·0 128·8 708·2 146·3
Bill & Melinda 
Gates 
Foundation
·· ·· ·· ·· ·· ·· 377·8 30·1 376·1 42·0 740·0 128·8 708·2 146·3
Grand total 2673·0 2688·7 3673·3 4454·9 4770·0 5529·0 7222·4 3587·3 7142·4 3804·8 7560·6 4673·7 8344·8 4498·6
Disbursements are in constant 2012 US$ (millions). MNCH=maternal, newborn, and child health. R*=reproductive health. AfDB=African Development Bank. AfDF=African Development Fund. AFESD=Arab Fund 
for Economic and Social Development. AsDB=Asian Development Bank. BADEA=The Arab Bank for Economic Development in Africa. GEF=Global Environment Fund. IDA=International Development Association. 
IDB Sp Fund=Inter-American Development Bank. IMF=International Monetary Fund. SAF=Structural Adjustment Facility. ESAF=Enhanced Structural Adjustment Facility. PRGF=Poverty Reduction and Growth 
Facility. OFID=OPEC Fund for International Development. UNAIDS=Joint United Nations Programme on HIV/AIDS. UNDP=United Nations Development Programme. UNECE=United Nations Economic Commission 
for Europe. UNFPA=United Nations Population Fund. UNPBF=United Nations Peace Building Fund. UNRWA=United Nations Relief and Works Agency for Palestine Refugees in the Near East . WFP=World Food 
Programme. GAVI=Global Alliance for Vaccines and Immunisation. ODA+=oﬃ  cial development assistance from the grants from the Bill and & Melinda Gates Foundation. *Correspond to the set of 31 donors that 
have consistently reported to the creditor reporting system of the Organisation for Economic Co-operation and Development.
Table 2: Worldwide ODA+ to reproductive, maternal, newborn, and child health by type and name of donor, 2003–12
See Online for appendix
Articles
e415 www.thelancet.com/lancetgh   Vol 3   July 2015
2011; table 1; appendix p 2). In 2012, the 31 donors 
reporting consistently to the credit reporting system 
accounted for 92·4% of the disbursements received by 
the 75 Countdown countries (appendix p 3).
The proportion of ODA for MNCH explicitly 
mentioning a term or activity for newborns increased 
sharply from 1·6% in 2003 to 18·4% in 2012 (table 1; 
appendix p 2). More than $1 billion went to projects that 
mentioned newborns in 2012 compared with $33 million 
in 2003 (a 34-fold increase; table 1). In 2012, $6·0 million 
were devoted to projects exclusively beneﬁ ting newborns, 
representing 0·3% of ODA to maternal and newborn 
health (a 6·5-fold increase relative to 2003).
In 2011 and 2012, more than half of ODA+ to MNCH to 
all countries worldwide was from bilateral agencies and 
slightly less than a quarter from multilateral agencies, 
2003 2004 2005 2006 2007 2008
MNCH % MNCH % MNCH % MNCH % MNCH % MNCH %
General budget support 72 3·5% 99 4·4% 99 3·4% 141 3·9% 157 4·3% 94 2·2%
Sector budget support 5 0·2% 6 0·3% 44 1·5% 87 2·4% 141 3·9% 134 3·1%
Basket-funding 55 2·7% 83 3·7% 69 2·3% 50 1·4% 70 1·9% 178 4·1%
Projects 1916 93·6% 2036 91·5% 2724 92·8% 3349 92·3% 3273 89·9% 3961 90·7%
HIV (speciﬁ c to MNCH) 3 0·2% 4 0·2% 22 0·8% 25 0·8% 87 2·7% 45 1·1%
Malaria 89 4·7% 136 6·7% 280 10·3% 387 11·6% 347 10·6% 549 13·9%
Immunisation 479 25·0% 605 29·7% 496 18·2% 531 15·8% 658 20·1% 801 20·2%
Other child health activities 96 5·0% 93 4·6% 223 8·2% 171 5·1% 250 7·6% 186 4·7%
HIV (not speciﬁ c to MNCH) 40 2·1% 67 3·3% 71 2·6% 58 1·7% 131 4·0% 122 3·1%
Reproductive health 427 22·3% 363 17·8% 732 26·9% 482 14·4% 667 20·4% 825 20·8%
Nutrition 75 3·9% 90 4·4% 127 4·7% 330 9·8% 182 5·6% 171 4·3%
General health care, 
including health systems
707 36·9% 678 33·3% 773 28·4% 1365 40·8% 950 29·0% 1262 31·9%
Total 2047 ·· 2224 ·· 2936 ·· 3627 ·· 3641 ·· 4367 ··
Disbursement are in constant 2012 US$ (millions). Percentage values represent the proportion of total ODA except for project lines where percentage values represent the 
proportion of the total project-based ODA. MNCH=maternal, newborn, and child health. R*=Reproductive health. ODA=oﬃ  cial development assistance.
Table 3: ODA to maternal, newborn, and child health to the 75 Countdown priority countries from the 31 donors reporting consistently to the creditor 
reporting system of the Organisation for Economic Co-operation and Development, by type of ODA and purpose of projects between 2003 and 2008
2009 2010 2011 2012
MNCH % R* % MNCH % R* % MNCH % R* % MNCH % R* %
General budget support 82 1·6% ·· ·· 82 1·6% ·· ·· 83 1·6% ·· ·· 54 0·9% ·· ··
Sector budget support 43 0·9% ·· ·· 64 1·2% ·· ·· 60 1·1% ·· ·· 62 1·0% ·· ··
Basket-funding 303 5·9% ·· ·· 300 5·7% ·· ·· 180 3·4% ·· ·· 89 1·4% ·· ··
Projects 4672 91·6% 2615 ·· 4776 91·5% 2828 ·· 4961 93·9% 3021 ·· 5966 96·7% 3119 ··
HIV (speciﬁ c to MNCH) 94 2·0% ·· ·· 114 2·4% ·· ·· 46 0·9% ·· ·· 59 1·0% ·· ··
Malaria 970 20·8% ·· ·· 981 20·5% ·· ·· 816 16·4% ·· ·· 1087 18·2% ·· ··
Immunisation 665 14·2% ·· ·· 824 17·3% ·· ·· 854 17·2% ·· ·· 1063 17·8% ·· ··
Other child health activities 204 4·4% ·· ·· 209 4·4% ·· ·· 260 5·2% ·· ·· 175 2·9% ·· ··
HIV (not speciﬁ c to MNCH) 157 3·4% 2226 85·2% 172 3·6% 2371 83·9% 260 5·2% 2528 83·7% 254 4·3% 2565 82·2%
Reproductive health 1081 23·1% 139 5·3% 1053 22·0% 151 5·4% 911 18·4% 72 2·4% 1206 20·2% 44 1·4%
Family planning ·· ·· 63 2·4% ·· ·· 55 2·0% ·· ·· 384 12·7% ·· ·· 462 14·8%
Sexually transmitted infections ·· ·· 118 4·5% ·· ·· 163 5·8% ·· ·· 16 0·5% ·· ·· 14 0·4%
Sexual health ·· ·· 68 2·6% ·· ·· 87 3·1% ·· ·· 21 0·7% ·· ·· 34 1·1%
Nutrition 337 7·2% ·· ·· 341 7·1% ·· ·· 401 8·1% ·· ·· 577 9·7% ·· ··
General health care, including 
health systems
1166 25·0% ·· ·· 1081 22·6% ·· ·· 1413 28·5% ·· ·· 1545 25·9% ·· ··
Total 5101 ·· 2615 ·· 5221 ·· 2828 ·· 5284 ·· 3021 ·· 6170 ·· 3119 ··
Disbursement are in constant 2012 US$ (millions). Percentage values represent the proportion of total ODA except for project lines where percentage values represent the proportion of total project-based ODA. 
MNCH=maternal, newborn, and child health. R*=reproductive health. ODA=oﬃ  cial development assistance.
Table 4: ODA to reproductive, maternal, newborn, and child health to the 75 Countdown priority countries from the 31 donors reporting consistently to the creditor reporting system of 
the Organisation for Economic Co-operation and Development, by type of ODA and purpose of projects between 2009 and 2012
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2003 
(MNCH)
2004 
(MNCH)
2005 
(MNCH)
2006 
(MNCH)
2007 
(MNCH)
2008 
(MNCH)
2009 2010 2011 2012
MNCH R* MNCH R* MNCH R* MNCH R*
Afghanistan 48·1 48·0 83·9 86·7 121·6 195·7 263·3 27·8 224·2 20·2 283·1 35·1 262·0 34·8
Angola 21·1 15·3 61·1 25·4 52·4 67·2 49·1 9·8 46·5 13·2 33·1 14·9 56·2 14·2
Azerbaijan 1·6 2·1 4·1 3·2 3·7 5·6 6·5 2·3 7·8 4·8 9·0 2·0 6·2 1·9
Bangladesh 82·9 95·4 142·1 187·8 81·2 144·0 196·9 8·9 200·8 13·3 196·5 26·9 190·2 21·3
Benin 14·6 18·7 18·0 34·7 32·4 39·1 53·0 15·8 52·5 19·5 51·5 18·4 45·3 8·4
Bolivia 30·2 27·7 22·3 60·2 37·2 30·0 34·9 9·8 36·5 5·8 30·8 12·0 31·5 8·9
Botswana 3·3 1·3 1·5 1·5 2·6 61·2 5·1 123·9 4·8 42·3 3·1 42·8 1·8 27·7
Brazil 10·6 9·9 3·8 6·0 3·8 6·5 7·1 2·9 11·1 4·0 11·7 2·8 3·3 2·0
Burkina Faso 17·8 27·6 36·8 74·9 49·5 57·7 67·4 28·1 99·5 21·7 57·8 8·7 100·2 15·4
Burundi 12·8 13·9 21·3 19·7 29·9 37·6 34·7 18·4 54·9 8·4 51·0 13·8 39·7 11·5
Cambodia 19·9 11·4 26·7 23·9 32·5 41·1 58·7 35·0 84·3 28·3 59·2 43·6 59·0 24·9
Cameroon 10·0 14·4 27·1 29·4 20·0 23·0 31·9 16·6 26·0 8·6 83·4 8·1 40·0 14·3
Central African 
Republic
3·5 8·4 8·2 9·3 12·2 13·7 12·9 3·3 13·8 5·8 18·1 4·2 11·2 2·9
Chad 11·7 19·5 20·3 11·9 20·8 26·1 28·1 4·4 54·7 7·5 33·9 10·4 34·0 4·4
China 66·4 65·2 56·9 69·0 90·0 61·8 63·5 52·4 63·1 41·9 26·0 40·6 40·4 42·7
Comoros 3·5 2·7 2·1 1·4 1·5 1·2 2·1 0·1 5·7 0·1 3·2 0·5 4·3 0·4
DR Congo 37·1 59·7 68·2 88·6 115·6 202·3 227·9 37·0 249·5 68·2 302·4 55·7 310·9 68·2
Congo (Brazzaville) 4·6 5·1 4·4 3·0 7·0 9·2 5·0 3·4 20·8 6·3 13·4 5·7 9·5 2·4
Côte d’Ivoire 12·8 17·8 11·5 10·5 25·3 38·0 38·5 37·0 65·5 45·7 52·5 39·6 51·5 43·3
Djibouti 1·4 4·4 5·9 6·0 14·2 6·5 8·4 1·6 5·2 1·7 6·4 1·3 12·3 0·6
Egypt 11·0 15·1 35·8 50·3 30·7 31·5 26·6 9·3 31·2 5·6 23·7 5·2 23·6 1·4
Equatorial Guinea 1·1 1·4 2·8 5·8 4·2 8·0 6·4 0·7 6·5 1·0 2·4 0·3 1·1 0·1
Eritrea 21·7 18·1 18·4 13·4 16·9 12·7 13·0 9·4 28·8 11·9 12·7 3·9 11·7 9·2
Ethiopia 109·1 75·0 99·9 245·4 238·0 202·3 321·6 122·1 225·1 218·5 349·9 230·7 381·4 166·0
Gabon 0·9 3·6 5·3 4·5 4·3 2·3 3·9 2·7 1·5 1·5 1·7 1·8 1·3 1·3
Gambia 5·6 6·7 9·8 4·3 8·3 6·9 8·3 3·7 12·0 3·6 9·0 3·6 8·6 3·0
Ghana 59·8 79·0 93·3 102·2 81·5 83·2 122·1 38·7 120·6 22·9 109·4 40·7 172·8 25·0
Guatemala 18·2 11·3 17·9 21·4 27·0 35·4 25·6 10·6 17·7 7·7 22·7 13·7 21·5 10·6
Guinea 9·2 8·7 17·5 12·7 12·9 14·1 19·0 8·1 30·6 6·8 15·0 12·3 45·2 7·1
Guinea-Bissau 3·4 3·0 4·9 3·5 6·2 7·0 6·5 3·6 12·4 4·0 6·7 2·6 3·8 0·9
Haiti 5·3 13·9 11·1 22·4 37·7 43·5 41·4 92·2 108·3 89·4 153·7 86·5 81·9 87·4
India 271·7 363·7 432·6 230·4 350·1 374·1 365·1 102·7 373·1 70·0 253·5 137·0 321·8 73·4
Indonesia 75·6 68·3 58·5 120·6 87·0 94·9 98·6 19·4 98·4 14·8 64·1 22·5 93·0 25·4
Iraq 54·3 24·3 113·8 95·5 104·8 25·6 44·7 0·9 42·3 0·6 35·2 0·1 21·0 1·8
Kenya 64·8 64·2 90·1 115·0 92·0 139·0 167·2 207·6 209·8 224·7 194·6 280·9 224·9 351·7
North Korea 4·9 3·7 5·5 4·5 10·3 7·2 9·8 0·0 11·6 0·0 7·9 0·0 12·3 0·6
Kyrgyzstan 20·1 9·1 11·8 12·3 14·1 14·6 14·6 1·9 15·8 2·4 15·0 3·1 13·4 2·5
Laos 11·9 8·1 14·8 11·9 17·3 17·8 17·8 3·0 22·1 2·8 21·7 4·8 23·2 2·4
Lesotho 3·2 3·8 1·6 2·1 4·4 7·0 5·3 16·4 12·8 26·6 16·9 35·6 15·6 41·3
Liberia 9·8 12·8 8·2 17·3 25·1 38·9 54·7 6·0 53·6 11·4 81·1 15·8 57·5 11·5
Madagascar 34·6 38·1 42·7 120·4 55·8 63·7 50·5 6·7 96·5 10·5 61·6 10·4 57·9 15·1
Malawi 51·7 42·7 42·3 87·8 98·3 103·5 155·6 31·9 91·0 62·6 124·5 67·9 154·7 99·0
Mali 20·4 27·7 38·3 70·5 52·4 56·7 67·9 17·5 89·3 14·8 119·5 17·0 134·2 20·1
Mauritania 7·8 8·2 4·5 17·8 10·0 9·1 11·7 0·3 12·7 0·0 11·2 1·2 27·7 1·4
Mexico 6·4 4·7 5·9 4·7 5·0 2·6 2·1 1·1 2·7 1·2 2·1 3·0 3·3 3·9
Morocco 17·2 7·5 11·6 21·0 23·3 14·0 29·0 1·3 26·5 1·9 17·4 4·5 10·3 3·2
Mozambique 67·8 79·5 66·3 113·5 113·3 139·7 121·8 128·9 152·8 141·4 168·6 125·9 176·3 130·0
Myanmar 13·9 12·0 21·7 20·8 17·5 38·6 34·2 2·9 45·9 10·3 35·8 8·5 97·1 9·6
Nepal 22·6 13·6 25·0 30·9 38·8 55·7 52·8 9·7 79·6 11·2 54·3 16·3 50·1 13·8
(Table 5 continues on next page)
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with shares being similar to 2009 and 2010 (table 2; 
appendix p 2). The USA continued to be the largest 
source of funding for RMNCH, followed by the Global 
Fund (table 2). The President’s Emergency Plan for AIDS 
Relief (PEPFAR) accounted for $1·6 billion in 2011 and 
2012 of total US ODA to RMNCH (data not shown).
Funding from global health initiatives (Global Fund and 
GAVI) fell in 2011 to 17% of ODA+ to MNCH, from 21% in 
2010, and increased again in 2012 to 21% (table 2; appendix 
p 4). MNCH funding from GAVI increased by 2·1% in 
2011 relative to 2010 (from $697 million to $712 million), 
while funding from the Global Fund decreased by 34% in 
the same period (from $809 million to $537 million), due 
to reductions in funding for malaria (table 2).
More than 70% of ODA+ to R* comes from bilateral 
donors, with less than 20% coming from global health 
initiatives and less than 7% from multilaterals (table 2; 
appendix p 5). US contributions to R* exceeded 
$2·7 billion in 2011 and 2012, more than 3·5 times more 
than the next largest donor, and more than 1·9 times 
more than US contributions to MNCH.
The share of project-based funding to MNCH was at the 
highest level in 2012 (96·7%) since resource-tracking 
commenced (tables 3 and 4). The value of projects to 
strengthen health systems assumed to beneﬁ t RMNCH 
continued to increase in 2011 and 2012. Funding for 
immunisation and nutrition reached the highest levels 
since 2003, although ODA to immunisation represents a 
constant share of total MNCH funding since 2010. 
Two-thirds of nutrition funding was provided by Canada, 
the European Union, and Australia. Within ODA to R*, 
ODA to sexual health and sexually transmitted diseases 
has reduced, whereas ODA to HIV projects has continued 
to increase, accounting for more than 80% of all ODA to 
R* in 2011 and 2012. Funding to family planning increased 
seven-fold between 2009 and 2012, from $63·4 million in 
2009 to $462·3 million before the London Summit on 
Family Planning in 2012. This diﬀ erence is partly 
2003 
(MNCH)
2004 
(MNCH)
2005 
(MNCH)
2006 
(MNCH)
2007 
(MNCH)
2008 
(MNCH)
2009 2010 2011 2012
MNCH R* MNCH R* MNCH R* MNCH R*
(Continued from previous page)
Niger 14·7 17·2 25·1 63·8 47·0 67·4 63·2 10·9 87·8 3·8 69·2 11·4 98·5 6·8
Nigeria 68·7 94·0 111·4 157·2 193·7 268·9 462·0 220·0 225·6 222·3 296·8 207·3 396·6 239·5
Pakistan 82·4 72·3 106·7 164·1 188·0 190·8 248·8 13·5 318·4 13·8 277·3 22·8 389·5 29·8
Papua New Guinea 22·7 22·1 6·0 32·6 24·1 31·0 45·1 17·7 46·9 20·2 63·5 28·3 48·0 40·6
Peru 15·3 15·7 28·9 20·2 22·2 22·2 68·1 17·3 28·3 12·2 18·0 8·1 14·8 6·8
Philippines 24·0 16·1 14·0 18·7 32·4 25·5 43·1 18·1 60·9 11·0 45·2 21·2 34·2 20·1
Rwanda 17·9 31·1 30·7 55·7 44·8 84·9 96·0 74·1 71·7 114·6 88·0 107·7 78·7 114·5
São Tomé & Príncipe 1·6 1·7 2·4 2·0 7·7 3·2 1·7 0·1 2·8 0·1 4·6 0·7 2·8 0·4
Senegal 31·0 39·3 43·6 77·0 37·5 54·1 55·9 16·3 49·2 16·1 69·0 25·4 94·2 13·1
Sierra Leone 8·9 9·6 13·2 19·6 35·3 27·4 42·7 8·9 44·3 12·9 46·0 10·0 30·5 19·4
Solomon Islands 7·0 8·5 2·0 7·1 6·7 10·8 13·1 0·9 16·7 0·5 15·9 0·5 8·3 0·1
Somalia 8·1 11·0 10·2 17·0 29·0 35·5 57·2 1·8 47·3 6·6 28·1 5·6 99·0 1·8
South Africa 16·2 13·5 28·1 26·6 24·7 74·1 30·9 367·6 16·0 361·2 46·7 347·9 47·7 352·7
South Sudan 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 0·0 51·7 16·1 144·6 17·8
Sudan 14·7 42·0 82·0 65·8 101·2 128·9 140·8 9·1 178·9 26·7 128·0 9·9 175·1 4·9
Swaziland 1·1 0·3 1·4 1·2 2·8 3·2 4·5 16·3 3·7 34·5 8·3 32·2 4·0 26·9
Tajikistan 8·6 8·8 7·5 9·9 10·3 15·9 15·3 1·5 23·1 5·4 12·6 3·1 18·2 7·4
Tanzania 64·9 79·4 159·7 148·0 143·2 195·2 189·3 156·7 232·4 216·4 231·8 205·3 284·7 206·8
Togo 3·9 7·4 7·8 4·6 10·9 17·4 16·3 11·3 12·9 7·3 29·2 6·2 6·3 4·3
Turkmenistan 1·3 1·6 1·9 1·9 2·7 1·4 0·9 0·4 1·3 0·2 1·4 0·4 0·9 0·4
Uganda 67·8 79·5 87·7 186·5 98·3 119·0 124·7 153·1 114·5 159·5 116·7 167·9 192·6 234·7
Uzbekistan 7·5 6·6 9·3 11·4 12·4 16·1 17·5 3·2 17·7 1·5 13·1 3·4 12·8 6·8
Vietnam 50·9 44·6 59·3 58·5 49·6 69·5 65·2 30·9 78·3 25·9 92·9 35·0 34·9 23·5
Yemen 14·9 28·7 52·0 33·0 38·3 40·4 34·4 3·6 45·0 8·1 43·7 1·5 86·0 15·3
Zambia 59·3 66·7 86·1 83·0 96·0 103·5 95·0 123·8 65·4 120·6 106·7 144·2 122·9 141·0
Zimbabwe 15·8 9·8 20·6 25·4 41·2 44·0 75·9 40·0 74·2 78·9 61·9 56·1 187·9 114·5
Grand total 2047·1 2223·7 2935·7 3626·7 3640·6 4367·1 5100·6 2614·6 5221·5 2827·8 5284·3
Disbursements are in constant 2012 US$ (millions). MNCH=maternal, child, and newborn health. R*=Reproductive health. ODA=oﬃ  cial development assistance.
Table 5: ODA to reproductive, maternal, newborn, and child health to the 75 Countdown priority countries from the 31 donors reporting consistently to the creditor reporting system of 
the Organisation for Economic Co-operation and Development, 2003–12
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explained by a more than six-fold increase in funding 
from the USA between 2009 and 2012 from $42·3 million 
to $272·1 million (data not shown).
In 2011, ODA to MNCH reduced for 60% of the 75 priority 
countries relative to 2010, with an increase in MNCH noted 
for only 40% of countries. Half of the countries that had a 
reduction in ODA to MNCH in 2011 had a further reduction 
in 2012. Of the 75 priority countries, Ethiopia received the 
largest level of ODA to MNCH in 2011 and Nigeria received 
the largest level in 2012 (table 5). Turkmenistan received 
the lowest level of ODA to MNCH in both years. For R*, 
South Africa and Kenya received the highest levels of ODA 
in 2011 and 2012. North Korea and Iraq received the lowest 
levels of ODA to R* in 2011, replaced by Equatorial Guinea 
and the Solomon Islands in 2012.
Across the 75 Countdown priority countries, in 2011 
median ODA to child health per child reduced relative 
to 2010 to $14·8 (IQR 7·2–22·7) with a minor increase 
in 2012 to $15·4 (5·4–25·9; appendix pp 6, 7). Similarly, 
median ODA to MNH per livebirth reduced relative to 
2010 to $22·1 per livebirth (IQR 14·1–42·1) in 2011 
increasing to $26·6 (11·8–51·3) in 2012. Median ODA 
to R* per woman of reproductive age also reduced 
relative to 2010 to $7·3 per woman of reproductive age 
in 2011 (IQR 2·9–17·5), increasing to $8·1 in 2012 
(3·9–20·3).
Mexico, China, and Brazil—all middle-income 
countries—received the least ODA to child health per 
child, to MNH per livebirth and to R* per woman of 
reproductive age in 2011 and 2012. The Solomon Islands 
received the most for child health per child and for MNH 
per livebirth in both years. Swaziland, Lesotho, Zambia, 
and Botswana were among the top ﬁ ve recipients of 
reproductive health funding per woman of reproductive 
age in both years.
Results from the regression analyses show that ODA+ 
to RMNCH continues to be targeted to countries with 
increased levels of need (the signs on the coeﬃ  cients of 
Total Bilateral Multilateral Global health initiatives Private donors
Coeﬃ  cient 
(95% CI)
p value R² Coeﬃ  cient 
(95% CI)
p value R² Coeﬃ  cient 
(95% CI)
p value R² Coeﬃ  cient 
(95% CI)
p value R² Coeﬃ  cient 
(95% CI)
p value R²
Child health model
ln (ODA+ to CH per 
child, 2005)
0·014
(0·008 to 
0·019)
<0·001 0·12 0·010
(0·004 to 
0·016)
0·001 0·06 0·013
(0·006 to 
0·018)
<0·001 0·10 0·018
(0·013 to 
0·024)
<0·001 0·26 ·· ·· ··
ln (ODA+ to CH per 
child, 2010)
0·015
(0·001 to 
0·021)
<0·001 0·16 0·016
(0·001 to 
0·022)
<0·001 0·13 0·018
(0·011 to 
0·025)
<0·001 0·14 0·016
(0·009 to 
0·023)
<0·001 0·19 0·003
(–0·023 to 
0·030)
0·794 0·01
ln (ODA+ to CH per 
child, 2012)
0·016
(0·009 to 
0·022)
<0·001 0·12 0·015
(0·007 to 
0·021)
<0·001 0·10 0·018
(0·009 to 
0·026)
<0·001 0·11 0·024
(0·017 to 
0·032)
<0·001 0·27 0·004
(–0·005 to 
0·014)
0·390 0·01
Maternal and newborn health model
ln (ODA+ to MNH 
per livebirth, 2005)
0·001
(0·001 to 
0·002)
0·011 0·03 0·001
(–0·001 to 
0·001)
0·171 0·01 0·001
(0·001 to 
0·001)
0·026 0·03 0·001
(–0·001 to 
0·002)
0·139 0·04 ·· ·· ··
ln (ODA+ to MNH 
per livebirth, 2010)
0·002
(0·001 to 
0·003)
<0·001 0·07 0·001
(0·001 to 
0·003)
<0·001 0·06 0·002
(0·001 to 
0·002)
<0·001 0·07 0·001
(–0·001 to 
0·002)
0·102 0·03 0·001
(–0·001 to 
0·004)
0·326 0·07
ln (ODA+ to MNH 
per livebirth, 2012)
0·002
(0·001 to 
0·003)
0·001 0·06 0·002
(0·001 to 
0·003)
0·001 0·06 0·002
(0·001 to 
0·002)
0·001 0·05 0·001
(0·001 to 
0·002)
0·002 0·11 –0·002
(–0·006 to 
0·001)
0·211 0·07
Reproductive health model (HIV prevalence)
ln (ODA+ to R* per 
WRA, 2010)
0·157
(0·177 to 
0·192)
<0·001 0·27 0·181
(0·135 to 
0·227)
<0·001 0·22 0·074
(0·031 to 
0·117)
0·001 0·01 0·153
(0·110 to 
0·197)
<0·001 0·25 –0.026
(–0·144 to 
0·091)
0·634 0·02
ln (ODA+ to R* per 
WRA, 2012)
0·160
(0·122 to 
0·199)
<0·001 0·27 0·204
(0·155 to 
0·252)
<0·001 0·23 0·084
(0·046 to 
0·122)
<0·001 0·10 0·168
(0·110 to 
0·225)
<0·001 0·26 0·102
(0·002 to 
0·202)
0·045 0·13
Reproductive health model (female life expectancy at birth)
ln (ODA+ to R* per 
WRA, 2010)
–0·095
(–0·114 to 
–0·075)
<0·001 0·34 –0·113
(–0·139 to 
–0·086)
<0·001 0·29 –0·080
(–0·097 to 
–0·062)
<0·001 0·32 –0·065
(–0·089 to 
–0·041)
<0·001 0·20 –0·109
(–0·204 to 
0·154)
0·026 0·37
ln (ODA+ to R* per 
WRA, 2012)
–0·093
(–0·113 to 
–0·074)
<0·001 0·35 –0·122
(–0·149 to 
–0·095)
<0·001 0·34 –0·072
(–0·091 to 
–0·055)
<0·001 0·27 –0·077
(–0·998 to 
–0·055)
<0·001 0·30 –0·022
(–0·075 to 
0·029)
0·389 0·02
CH=child health. MNH=maternal and newborn health. R*=reproductive health. ln=natural logarithm. WRA=woman of reproductive age. ODA=oﬃ  cial development assistance.
 Table 6: Results of ordinary least squares regression models for worldwide ODA+ to all recipients
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the independent variables were as expected and statistically 
signiﬁ cant; table 6). However, we did not note evidence of 
an improvement in targeting to need for ODA+ to MNH, 
to child health, or to reproductive health between 2005, 
2010, and 2012, because there was no signiﬁ cant increase 
in the R2 values. When considering targeting to child 
health by type of donor, bilateral, multilateral, and global 
health initiatives showed evidence of targeting to need 
between 2005 and 2012. Private donors to child health do 
not show evidence of targeting according to need. When 
considering targeting to MNH by type of donor, bilateral 
donors were targeting to need in 2010 and 2012, but not in 
2005; global health initiatives were targeting to need in 
2012 but not in earlier years; multilateral donors were 
targeting to need in each year, whereas private donors 
show no evidence of targeting related to need. For the 
reproductive health model, bilateral, multilateral, and 
global health initiatives were targeting to need in each 
year. Private donors were targeting to need in the 2012 
HIV model and in 2010 in the life expectancy model. 
There was greater evidence of targeting for child and 
reproductive health compared with maternal and newborn 
health. The analysis of the R2 values does not indicate any 
signiﬁ cant increase in targeting over time for any of the 
donors in any of the models.
Discussion
This paper has increased the scope of previous 
Countdown tracking work by integrating funding for 
reproductive health and looking more closely at newborn 
health, thereby more fully reﬂ ecting the continuum of 
care for RMNCH (panel). Overall ODA+ decreased in 
2011 and increased marginally in 2012, yet ODA+ to 
RMNCH increased consistently during the same time 
period. Funding to R* increased during the period, 
although the rate of increase slowed between 2011 and 
2012 (and declined when considering all donors to all 
countries). R* remains heavily dominated by funding 
earmarked to HIV/AIDS, but there has been a surge in 
funding for family planning since 2011. The London 
Family Planning summit which took place in 2012 and 
the launch of the FP2020 are expected to further increase 
funding in this area.
Worldwide ODA+ to MNCH increased in 2011 by 5·9% 
relative to 2010 driven by increased funding to child 
health, which outweighed a reduction in funds for MNH. 
ODA to MNCH from the 31 consistent set of donors to 
the 75 priority countries increased by only 1·2% in 2011 
relative to 2010, but increased substantially between 2011 
and 2012. The period 2011 and 2012 saw an increase in 
funding for immunisation and MNH and a steady 
increase of funding to nutrition. Immunisation funding 
levels are likely to continue to increase as a result of 
donor pledges made during the Global Vaccine Summit 
in Abu Dhabi in April 24–25, 2013.
We noted an increase in the total funding to newborn 
health, with a much larger growth in projects that include 
newborns than those that exclusively target them. We 
believe this reﬂ ects a growing recognition of the linkage 
between MNH and the importance of newborn survival 
in reducing child mortality, with 44% of under-5 deaths 
being neonatal, and preterm birth now the leading cause 
of child deaths.25
Bilateral aid remains the dominant source of funding 
for RMNCH, with the USA remaining the biggest funder 
of RMNCH. Reliance on bilateral aid can result in greater 
volatility in aid disbursements in view of their sensitivity 
to macroeconomic conditions and domestic politics. For 
example, the countries most severely hit by the ﬁ nancial 
crisis decreased their ODA disbursements, with Spain 
reducing disbursements from $140 million in 2010 to 
$33 million in 2012; virtually no ODA was given by 
Greece in 2012, and Italy’s ODA ﬂ ows declined in 2012 to 
the same level as in 2003. Volatility of budgetary 
contributions has been shown to aﬀ ect recipient 
governments’ ability to plan,26 undertake long-term 
investment in health systems,27 and might result in 
governments reducing ﬁ nancing of the health sector 
(fungibility) to prepare for future shocks.28 Fluctuations 
in bilateral ODA might also have repercussions on 
multilateral funding; however, there is no evidence of 
this so far, and some bilateral organisations, including 
the UK and French Governments, have a clear policy to 
invest in multilateral agencies.29,30
This study showed evidence of a continued trend 
towards project-level funding relative to general budget 
and sector support. Research in Tanzania has shown 
that, despite budget support being preferred by recipient 
governments and being less subject to volatility, increased 
pressure to show results has led to development partners 
favouring project-based modalities.31
We report evidence that overall ODA+ remains targeted 
to countries with increased need, although we did not 
note evidence of improvement in targeting over time. 
There was greater evidence of targeting for child and 
reproductive health compared with maternal and 
newborn health. Clearly need is only one element in the 
decision to allocate funds and a range of political and 
economic and other factors also aﬀ ect these decisions.
Several resource-tracking exercises have been recently 
undertaken.6,9,32 The IHME recently reported that 
development assistance to health for MNCH grew by 
nearly 18% between 2010 and 2011, amounting to 
$6·1 billion in 2011,9 whereas we estimated that ODA+ to 
MNCH was $7·6 billion in 2011, an increase of 5·9% 
relative to 2010 (appendix p 8). The IHME has not yet 
reported data for 2012. The PMNCH report estimates 
that funding to RMNCH remained almost constant in 
2011 relative to 2010 at $9·6 billion (growing at 0·5% 
between 2010 and 2011; converted to 2012 prices from 
2005 prices).6 This value compares to our estimate of 
$8·3 billion in 2011, an increase of 3·2% relative to 2010. 
Like us, the PMNCH report estimates a surge in RMNCH 
funding in 2012 (growing to $10·4 billion, an increase of 
For more on Family Planning 
2020 see http://www.
familyplanning2020.org/
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8·8% relative to 2011, with our estimate at $9·3 million, 
an increase of 11·8%). The UNFPA and NIDI estimate 
international population assistance totalled $12·0 billion 
in 2011 and $12·4 billion in 2012.32 Their deﬁ nition of 
population activities includes the components of RMNH 
we analysed and support for demographic-related and 
programme-related data collection and analysis, research, 
policy development, and training and reporting, and 
excludes child health activities. In 2013, the OECD 
proposed a set of policy markers be introduced for 2014 
reporting on 2013 aid ﬂ ows in recognition of activities, 
which support the achievement of certain MDGs across 
multiple sectors. The RMNCH policy marker will 
facilitate tracking aid that is targeted to RMNCH and will 
be evaluated after a 2-year trial period.
Diﬀ erences in estimates reﬂ ect diﬀ erences in methods 
used by the various resource-tracking initiatives. First, 
there is variation in the sources of data used to track 
resources. IHME estimates development assistance to 
health, which includes all ﬁ nancial and in-kind 
contributions from global health channels which aim to 
improve health; 66% of the data analysed came from 
sources other than the creditor reporting system, whereas 
our analysis relies only on the creditor reporting system 
of the OECD and the donors who report to it. Donors 
such as China were not included in our assessment, yet 
their contributions to ODA have been estimated at 
slightly less than $4 billion per year.33 PMNCH and 
UNFPA also draw on the creditor reporting system data, 
but also held interviews and obtained ﬁ nancing data 
from additional organisations. Second, there is variation 
in the coding methods used. The IHME conducts an 
automated keyword search and allocates certain donors’ 
funding fully to MNCH, such as UNICEF, whereas our 
method is manual, coding projects with direct relevance 
to MNCH and including other non-purpose-speciﬁ c 
funding modalities, general health systems strengthening 
support, and general budget support that can be 
attributed to MNCH. PMNCH used the Muskoka 
method, which relies on the creditor reporting systems’ 
own coding system and assumes a ﬁ xed share of certain 
codes is allocated to RMNCH. Finally, there are 
diﬀ erences in the classiﬁ cation of RMNCH categories, 
which, do not aﬀ ect total RMNCH, but would aﬀ ect the 
breakdown by component—for example, IHME 
considers family planning to fall within MNCH, whereas 
we include it in R*.9 IHME excludes malaria, tuberculosis, 
and HIV/AIDS programmes from its estimates of aid for 
MNCH, whereas we include elements of each that are 
relevant to MNCH. Undoubtedly, an enhanced dialogue 
across these tracking initiatives is needed to reﬂ ect on 
the comparative advantages of the methods that have 
been used and lessons learnt to facilitate eventual future 
harmonisation of approaches. Agreement is needed as to 
which agency should take the lead.
The results shown in this paper are subject to the same 
limitations with regard to the methods that have been 
acknowledged previously.12–15 The ﬁ rst challenge relates to 
separating funding to R*, maternal and newborn health, 
and child health, as well as the programme components 
therein. Every record is assigned based on the project 
title and descriptions, which in some cases are complex, 
vague, or without information about beneﬁ ciaries. 
Moreover, 37% of our estimate of funding for MNCH 
was based on assumptions regarding the share of 
funding for the wider health sector, systems, or policy, 
which would beneﬁ t mothers and children. Literature 
informing these assumptions remains scarce and in-
depth country-level analyses are needed to understand 
who beneﬁ ts from health ﬁ nancing and how this might 
vary between countries. Although the estimates of 
funding to MNCH include health systems or pooled 
funding resource allocation, the estimate of R* is based 
only on direct project-level support and is thus likely to 
be an underestimate. Our models to assess targeting are 
simple and are not intended to unpack the full range of 
aid determinants, which would be an important area for 
future research. Finally, funding to R* is only estimated 
from 2009 to 2012 and does not include the period 
2003–08.
The continued increase in ODA+ to RMNCH at a time 
of falling overall aid contributions is encouraging, but 
additional improvements are needed to accelerate 
progress towards MDGs 4 and 5. Further research is 
needed to improve the accuracy of resource tracking for 
RMNCH, along with consensus on the way forward for 
harmonised and sustainable resource tracking post-2015.
Panel: Research in context
Systematic review
We reviewed previous resource tracking exercises including 
that of the Countdown,12–16 and reports by the Institute of 
Health Metrics and Evaluation9 and the Partnership for 
Maternal, Newborn and Child Health.6 Previous Countdown 
analyses were limited to maternal, newborn, and child 
health for the period 2003–12, or reproductive, maternal, 
and newborn health for the period 2009–12. Our study 
updates previous resource tracking done by Countdown for 
2013 and considers the full continuum of care for 
reproductive, maternal, newborn, and child health. 
Interpretation
This study contributes to the annual resource tracking of 
ODA+ disbursements to reproductive, maternal, newborn, 
and child health (RMNCH). Overall ODA+ decreased in 2011 
relative to 2010 and increased marginally in 2012, yet ODA+ 
to RMNCH increased consistently during the same time 
period. Funding to family planning and nutrition increased 
substantially, and ODA+ mentioning newborns continues to 
grow. ODA+ remains targeted to RMNCH need in terms of 
mortality and illness prevalence. This increase in funds to 
RMNCH is encouraging but continued improvements are 
needed to accelerate progress towards MDGs 4 and 5.
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